Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Shimizu, Masanori; Suzuki, Kunihiro; Kato, Kanako; Jojima, Teruo; Iijima, Toshie; Murohisa, Toshimitsu; Iijima, Makoto; Takekawa, Hidehiro; Usui, Isao; Hiraishi, Hideyuki; Aso, Yoshimasa

doi:10.1111/dom.13520

Public

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Published in Diabetes Obesity and Metabolism • Sep 3, 2018

Authors:

Masanori Shimizu

Kunihiro Suzuki

Kanako Kato

Abstract

AIMS: To investigate the effects of dapagliflozin on liver steatosis and fibrosis evaluated in patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). MATERIALS AND METHODS: In a randomized, active-controlled, open-label trial, 57 patients with type 2 diabetes and NAFLD were ran...

Subject

Dapagliflozin

Transient elastography

Steatosis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!